LNSR LENSAR INC

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights.

To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go to the Investors section of LENSAR’s website at Following the live webcast, an archived version of the call will be available on the website.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.

Contacts: Lee Roth / Cameron Radinovic
Thomas R. Staab, II, CFO Burns McClellan for LENSAR
  /


EN
31/10/2024

Underlying

LNSRLENSAR INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LENSAR INC

 PRESS RELEASE
Free
LNSR LENSAR INC

LENSAR® Provides Update on Pending Acquisition by Alcon

LENSAR® Provides Update on Pending Acquisition by Alcon ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the “FTC”) staff in connection with its Request for Additional Information and Documentary Material (the “Second Request”) and related r...

February 25, 2026 1 EN
 PRESS RELEASE
Free
LNSR LENSAR INC

LENSAR® Reports Third Quarter 2025 Results and Provides Business Updat...

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 20...

November 6, 2025 1 EN
 PRESS RELEASE
Free
LNSR LENSAR INC

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a cont...

September 2, 2025 1 EN
 PRESS RELEASE
Free
LNSR LENSAR INC

LENSAR Reports Second Quarter 2025 Results and Provides Business Updat...

LENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today an...

August 7, 2025 1 EN
 PRESS RELEASE
Free
LNSR LENSAR INC

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent r...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch